open access

Vol 54, No 5 (2020)
Research Paper
Submitted: 2020-06-23
Accepted: 2020-08-03
Published online: 2020-08-18
Get Citation

Usefulness of the Polish versions of the Montreal Cognitive Assessment 7.2 and the Mini-Mental State Examination as screening instruments for the detection of mild neurocognitive disorder

Natalia Sokołowska1, Remigiusz Sokołowski2, Eliza Oleksy1, Paulina Kasperska1, Karolina Klimkiewicz-Wszelaki1, Anna Polak-Szabela1, Marta Podhorecka1, Kornelia Kędziora-Kornatowska1
·
Pubmed: 32808669
·
Neurol Neurochir Pol 2020;54(5):440-448.
Affiliations
  1. Department of Geriatrics Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, M. Curie-Skłodowskiej Street 9, 85 – 094 Bydgoszcz, Poland
  2. Clinic Neurosurgery and Neurology, Stroke Care Unit, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz

open access

Vol 54, No 5 (2020)
Research papers
Submitted: 2020-06-23
Accepted: 2020-08-03
Published online: 2020-08-18

Abstract

Introduction. Screening tests are a key step in the diagnosis of dementia and should therefore be highly sensitive to the detection of mild neurocognitive disorders (NCD). The Mini Mental State Examination (MMSE) is the most commonly used screening method. The Montreal Cognitive Assessment (MoCA) is a newer and less well-known screening tool, which has none of the limitations of the MMSE.

Aim.
The aim of this study was to analyse the reliability of the Polish versions of MoCA 7.2 vs MMSE in the detection of mild NCD among people aged over 60.

Material and methods. The study was carried out at the Department and Clinic of Geriatrics from September 2014 to March 2017. The study included 281 participants, 91 of whom were assigned to the group without NCD. The other 190 had been diagnosed with mild NCD.

Results. In the analysis of the ROC curve of the MoCA 7.2 results, the AUC was 0.925 (p < 0.001). The optimal cut-off point for mild NCD was 23/24 points, with sensitivity and specificity of 83.2% and 79.1%. In the ROC curve of MMSE results, the AUC was 0.847 (p < 0.001). The optimal cut-off point for mild NCD was 27/28 points, with sensitivity and specificity of 75.8% and 66.7%. The difference between AUC MoCA 7.2 and MMSE was 0.078 (p = 0.036).

Conclusions. MoCA 7.2 detects mild NCD with more sensitivity than MMSE. We recommend using the cut-off point for MoCA of 23/24 points, because this is characterised by a higher sensitivity than the previously recommended cut-off point of 25/26 points. For the MMSE, the recommended cut-off point should be 27/28, which gives greater diagnostic accuracy than the previously recommended 25/26 points.

Abstract

Introduction. Screening tests are a key step in the diagnosis of dementia and should therefore be highly sensitive to the detection of mild neurocognitive disorders (NCD). The Mini Mental State Examination (MMSE) is the most commonly used screening method. The Montreal Cognitive Assessment (MoCA) is a newer and less well-known screening tool, which has none of the limitations of the MMSE.

Aim.
The aim of this study was to analyse the reliability of the Polish versions of MoCA 7.2 vs MMSE in the detection of mild NCD among people aged over 60.

Material and methods. The study was carried out at the Department and Clinic of Geriatrics from September 2014 to March 2017. The study included 281 participants, 91 of whom were assigned to the group without NCD. The other 190 had been diagnosed with mild NCD.

Results. In the analysis of the ROC curve of the MoCA 7.2 results, the AUC was 0.925 (p < 0.001). The optimal cut-off point for mild NCD was 23/24 points, with sensitivity and specificity of 83.2% and 79.1%. In the ROC curve of MMSE results, the AUC was 0.847 (p < 0.001). The optimal cut-off point for mild NCD was 27/28 points, with sensitivity and specificity of 75.8% and 66.7%. The difference between AUC MoCA 7.2 and MMSE was 0.078 (p = 0.036).

Conclusions. MoCA 7.2 detects mild NCD with more sensitivity than MMSE. We recommend using the cut-off point for MoCA of 23/24 points, because this is characterised by a higher sensitivity than the previously recommended cut-off point of 25/26 points. For the MMSE, the recommended cut-off point should be 27/28, which gives greater diagnostic accuracy than the previously recommended 25/26 points.

Get Citation

Keywords

mild neurocognitive disorder, Mini Mental State Examination, Montreal Cognitive Assessment, screening tests

About this article
Title

Usefulness of the Polish versions of the Montreal Cognitive Assessment 7.2 and the Mini-Mental State Examination as screening instruments for the detection of mild neurocognitive disorder

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 54, No 5 (2020)

Article type

Research Paper

Pages

440-448

Published online

2020-08-18

Page views

1549

Article views/downloads

599

DOI

10.5603/PJNNS.a2020.0064

Pubmed

32808669

Bibliographic record

Neurol Neurochir Pol 2020;54(5):440-448.

Keywords

mild neurocognitive disorder
Mini Mental State Examination
Montreal Cognitive Assessment
screening tests

Authors

Natalia Sokołowska
Remigiusz Sokołowski
Eliza Oleksy
Paulina Kasperska
Karolina Klimkiewicz-Wszelaki
Anna Polak-Szabela
Marta Podhorecka
Kornelia Kędziora-Kornatowska

References (51)
  1. Departament Badań Demograficznych i Rynku Pracy. Sytuacja demograficzna osób starszych i konsekwencje starzenia się ludności Polski w świetle prognozy na lata 2014-2050. Warszawa: Główny Urząd Pracy. ; 2014.
  2. Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013; 9(1): 63–75.e2.
  3. Gustavsson A, Svensson M, Jacobi F, et al. CDBE2010Study Group. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011; 21(9): 655–679.
  4. Jeste DV, Lieberman JA, Fassler D, et al. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington: American Psychiatric Association. ; 2013.
  5. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol. 2003; 2(1): 15–21.
  6. Bloudek LM, Spackman DE, Blankenburg M, et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J Alzheimers Dis. 2011; 26(4): 627–645.
  7. Barc K, Kuźma-Kozakiewicz M. Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Neurol Neurochir Pol. 2019; 53(2): 99–112.
  8. Lin JS, O'Connor E, Rossom RC, et al. Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality. ; 2013.
  9. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018; 90(3): 126–135.
  10. Cullen B, O'Neill B, Evans JJ, et al. A review of screening tests for cognitive impairment. J Neurol Neurosurg Psychiatry. 2007; 78(8): 790–799.
  11. Daroff R, Jankovic J, Mazziotta J, et al. Bradley's Neurology in Clinical Practice. Seventh Edition Elsevier. ; 2016.
  12. Iracleous P, Nie JX, Tracy CS, et al. Primary care physicians' attitudes towards cognitive screening: findings from a national postal survey. Int J Geriatr Psychiatry. 2010; 25(1): 23–29.
  13. Breton A, Casey D, Arnaoutoglou NA. Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: Meta-analysis of diagnostic accuracy studies. Int J Geriatr Psychiatry. 2019; 34(2): 233–242.
  14. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4): 695–699.
  15. Coen RF, Robertson DA, Kenny RA, et al. Strengths and Limitations of the MoCA for Assessing Cognitive Functioning: Findings From a Large Representative Sample of Irish Older Adults. J Geriatr Psychiatry Neurol. 2016; 29(1): 18–24.
  16. Gierus J, Mosiołek A, Koweszko T, et al. Montrealska Skala Oceny Funkcji Poznawczych MoCA 7.2 – polska adaptacja metody i badania nad równoważnością. Psychiatr Pol. 2015; 49(1): 171–179.
  17. Folstein M, Folstein S, McHugh P. “Mini-mental state”. Journal of Psychiatric Research. 1975; 12(3): 189–198.
  18. de Silva V, Hanwella R. Why are we copyrighting science? BMJ. 2010; 341: c4738.
  19. Zarządzenie Nr 72/2011/DSOZ Prezesa Narodowego Funduszu Zdrowia z dnia 20 października 2011 r. w sprawie określenia warunków zawierania i realizacji umów w rodzaju: leczenie szpitalne WEB: www.nfz.gov.pl/zarzadzenia-prezesa/zarzadzenia-prezesa-nfz/zarzadzenie-nr-722011dsoz, 4642. html, access 25. ; 04: 2016.
  20. Mendes-Santos LC, Mograbi D, Spenciere B, et al. Specific algorithm method of scoring the Clock Drawing Test applied in cognitively normal elderly. Dement Neuropsychol. 2015; 9(2): 128–135.
  21. Shulman K, Shedletsky R, Silver I. The challenge of time: Clock-drawing and cognitive function in the elderly. International Journal of Geriatric Psychiatry. 1986; 1(2): 135–140.
  22. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982; 17(1): 37–49.
  23. Katz S, Downs TD, Cash HR, et al. Progress in development of the index of ADL. Gerontologist. 1970; 10(1): 20–30.
  24. Wieczorowska-Tobis K, Talarska D. Geriatria i pielęgniarstwo geriatryczne. Warszawa: Wydawnictwo Lekarskie PZWL. ; 2010.
  25. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969; 9(3): 179–186.
  26. Magierska J, Magierski R, Fendler W, et al. Clinical application of the Polish adaptation of the Montreal Cognitive Assessment (MoCA) test in screening for cognitive impairment. Neurol Neurochir Pol. 2012; 46(2): 130–139.
  27. Damian AM, Jacobson SA, Hentz JG, et al. The Montreal Cognitive Assessment and the mini-mental state examination as screening instruments for cognitive impairment: item analyses and threshold scores. Dement Geriatr Cogn Disord. 2011; 31(2): 126–131.
  28. Roalf DR, Moberg PJ, Xie SX, et al. Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimers Dement. 2013; 9(5): 529–537.
  29. Trzepacz PT, Hochstetler H, Wang S, et al. Alzheimer’s Disease Neuroimaging Initiative. Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatr. 2015; 15: 107.
  30. Fujiwara Y, Suzuki H, Yasunaga M, et al. Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int. 2010; 10(3): 225–232.
  31. Memória CM, Yassuda MS, Nakano EY, et al. Brief screening for mild cognitive impairment: validation of the Brazilian version of the Montreal cognitive assessment. Int J Geriatr Psychiatry. 2013; 28(1): 34–40.
  32. Kaya Y, Aki OE, Can UA, et al. Validation of Montreal Cognitive Assessment and Discriminant Power of Montreal Cognitive Assessment Subtests in Patients With Mild Cognitive Impairment and Alzheimer Dementia in Turkish Population. J Geriatr Psychiatry Neurol. 2014; 27(2): 103–109.
  33. Chang, Y.T., Chang C.C., Lin H.S., Huang C.W., Chang W.N., Lui C.C., Montreal cognitive assessment in assessing clinical severity and white matter hyperintensity in Alzheimer's disease with normal control comparison. Acta Neurol Taiwan. 2012; 21(2): 64–73.
  34. Yu J, Li J, Huang X. The Beijing version of the Montreal Cognitive Assessment as a brief screening tool for mild cognitive impairment: a community-based study. BMC Psychiatry. 2012; 12: 156.
  35. Ismail Z, Smith EE, Geda Y, et al. ISTAART Neuropsychiatric Symptoms Professional Interest Area. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016; 12(2): 195–202.
  36. Ciobica A, Padurariu M, Ciobica A, et al. General issues encountered while diagnosing mild cognitive impairment in Romanian patients. Int J Geriatr Psychiatry. 2017; 32(1): 116–117.
  37. Gil L, Ruiz de Sánchez C, Gil F, et al. Validation of the Montreal Cognitive Assessment (MoCA) in Spanish as a screening tool for mild cognitive impairment and mild dementia in patients over 65 years old in Bogotá, Colombia. Int J Geriatr Psychiatry. 2015; 30(6): 655–662.
  38. Razali R, Jean-Li L, Jaffar A, et al. Is the Bahasa Malaysia version of the Montreal Cognitive Assessment (MoCA-BM) a better instrument than the Malay version of the Mini Mental State Examination (M-MMSE) in screening for mild cognitive impairment (MCI) in the elderly? Compr Psychiatry. 2014; 55 Suppl 1: S70–S75.
  39. Ng A, Chew I, Narasimhalu K, et al. Effectiveness of Montreal Cognitive Assessment for the diagnosis of mild cognitive impairment and mild Alzheimer's disease in Singapore. Singapore Med J. 2013; 54(11): 616–619.
  40. Borland E, Nägga K, Nilsson PM, et al. The Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-Based Cohort. J Alzheimers Dis. 2017; 59(3): 893–901.
  41. Martinelli JE, Cecato JF, Bartholomeu D, et al. Comparison of the diagnostic accuracy of neuropsychological tests in differentiating Alzheimer's disease from mild cognitive impairment: can the montreal cognitive assessment be better than the cambridge cognitive examination? Dement Geriatr Cogn Dis Extra. 2014; 4(2): 113–121.
  42. Smith T, Gildeh N, Holmes C. The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatry. 2007; 52(5): 329–332.
  43. Luis CA, Keegan AP, Mullan M. Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the Southeastern US. Int J Geriatr Psychiatry. 2009; 24(2): 197–201.
  44. Rahman TT, El Gaafary MM. Montreal Cognitive Assessment Arabic version: reliability and validity prevalence of mild cognitive impairment among elderly attending geriatric clubs in Cairo. Geriatr Gerontol Int. 2009; 9(1): 54–61.
  45. Lee JY, Cho SJ, Na DL, et al. Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal Cognitive Assessment. J Geriatr Psychiatry Neurol. 2008; 21(2): 104–110.
  46. Mitchell AJ. A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res. 2009; 43(4): 411–431.
  47. Tsoi KKF, Chan JYC, Hirai HW, et al. Recall Tests Are Effective to Detect Mild Cognitive Impairment: A Systematic Review and Meta-analysis of 108 Diagnostic Studies. J Am Med Dir Assoc. 2017; 18(9): 807.e17–807.e29.
  48. Ciesielska N, Sokołowski R, Mazur E, et al. Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. Psychiatr Pol. 2016; 50(5): 1039–1052.
  49. Gagnon G, Hansen KT, Woolmore-Goodwin S, et al. Correcting the MoCA for education: effect on sensitivity. Can J Neurol Sci. 2013; 40(5): 678–683.
  50. Brayne C, Calloway P. The association of education and socioeconomic status with the Mini Mental State Examination and the clinical diagnosis of dementia in elderly people. Age Ageing. 1990; 19(2): 91–96.
  51. Grigoletto F, Zappalà G, Anderson DW, et al. Norms for the Mini-Mental State Examination in a healthy population. Neurology. 1999; 53(2): 315–320.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl